POST Online Media Lite Edition



 

Perrigo appoints Uwe Röhrhoff as CEO

Staff Writer |
Dublin, United Kingdom - Perrigo Company, a provider of healthcare products, announced the appointment of Uwe Röhrhoff as chief executive officer, effective January 15, 2018.

Article continues below




Mr. Röhrhoff has more than 25 years of experience with Gerresheimer.

He began his career with Gerresheimer AG in 1991, steadily advancing within the organization to serve in a number of key leadership roles in Europe and North America.

Mr. Röhrhoff was appointed to build out the Company's business in the United States (1996-1998) and head the American subsidiary Gerresheimer Glass Inc. (2001-2010).

He served as an executive board member (2003-2017), responsible for two of the company's three business units, and CEO (2010-2017) of Gerresheimer AG until his retirement in August 2017.

Mr. Röhrhoff brings with him an extensive operational track record.

He led an organization that included 36 manufacturing facilities across 14 countries, delivering products to 1,500 customers, including the 10 largest global pharmaceutical companies, in nearly 100 countries.

Mr. Röhrhoff was instrumental in determining Gerresheimer AG's strategic focus, transforming and reshaping the corporate portfolio and delivering on operational projects.

Mr. Röhrhoff serves as Audit Committee Chairman on the Board of Directors of Catalent, Inc., a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products.

He is also Deputy Chairman of Klöckner&Co SE, one of the world's largest producer-independent steel and metal distributors.

Mr. Röhrhoff plans to step down from both boards.

 LATEST MOVES FROM United Kingdom 

PZ Cussons appoints Valeria Juarez as director
BT appoints Adam Crozier as chairman
Craig Butterworth joins Droit as chief commercial officer
Burberry director Carolyn McCall to retire
Burberry CEO Marco Gobbetti to step down

What to read next

Perrigo announces leadership change in Rx pharmaceuticals segment
Perrigo expands the responsibilities of EVP Sharon Kochan
Perrigo names John Hendrickson CEO